Japan’s general trading houses are steadily becoming a force to be reckoned with in the pharmaceutical industry — and not…
COMMENTARY
Vascular Calcification: Ultimate Consequnce of Vascular Atherosclerosis (II) -1-
Keiji Nakamura, Ph. D.Pharma Forum Institute, Kamakura, JapanNatural Prevention Mechanismsof Vascular CalcificationMatrix Gamma-carboxyglutamateProtein (MGP) and Vitamin KMatrix gamma-carboxyglutamate (Gla) protein (MGP), a vitamin K-dependent protein, is a potent in vivo inhibitor of arterial calcification. In healthy arteries, MGP was mainly…
To read the full story
COMMENTARY
- Japan’s Trading Houses Gain Ground in Pharma, Rewriting the Industry Playbook
November 10, 2025
- The Price of Stability: Who Bears Japan’s Drug Distribution Burden?
October 27, 2025
- Inside Eylea - 2: Will a Bio-AG Return after Six Years? Pricing Debate Resumes
October 7, 2025
- Inside Eylea - 1: Patent Issues Behind Differences in Biosimilar Indications for AMD and DME
October 6, 2025
- FPMAJ Chair’s Call for Blanket Drug Price Hike: Bold Pitch or Wild Throw?
September 30, 2025
A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…